In contrast to the clinical drug cisplatin, the anticancer complex [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ [1-I] is inert towards hydrolysis and targets cancer cell metabolism rather than DNA. A combination of DFT calculations and X-ray absorption spectroscopy (XAS) suggests that hydrolytic activation of 1-I involves catalytic attack by the intracellular tripeptide glutathione (GSH) on the azo bond of the chelating ligand in the complex.
Glutathione activation of an organometallic half-sandwich anticancer drug candidate by ligand attack
Borfecchia E.;Martini A.;
2019-01-01
Abstract
In contrast to the clinical drug cisplatin, the anticancer complex [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ [1-I] is inert towards hydrolysis and targets cancer cell metabolism rather than DNA. A combination of DFT calculations and X-ray absorption spectroscopy (XAS) suggests that hydrolytic activation of 1-I involves catalytic attack by the intracellular tripeptide glutathione (GSH) on the azo bond of the chelating ligand in the complex.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
19_Zhang_ChemCommun_OsComplexAct_EDIT.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
2.57 MB
Formato
Adobe PDF
|
2.57 MB | Adobe PDF | Visualizza/Apri |
|
19_Zhang_ChemCommun_OsComplexAct_OA.pdf
Open Access dal 21/11/2020
Descrizione: Articolo principale open access
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
